Provided by Tiger Fintech (Singapore) Pte. Ltd.

Protalix BioTherapeutics

1.45
-0.0500-3.33%
Post-market: 1.450.00000.00%16:09 EDT
Volume:514.63K
Turnover:766.20K
Market Cap:115.43M
PE:30.11
High:1.52
Open:1.51
Low:1.45
Close:1.50
Loading ...

Kepler Capital Sticks to Its Buy Rating for PLUXEE N.V. (PLX)

TIPRANKS
·
24 Apr

Protalix BioTherapeutics' CFO Rubin to Leave

Dow Jones
·
24 Apr

UBS Reaffirms Their Hold Rating on PLUXEE N.V. (PLX)

TIPRANKS
·
23 Apr

PLUXEE N.V. (PLX) Gets a Hold from Barclays

TIPRANKS
·
22 Apr

Protalix BioTherapeutics And 2 Other Promising Penny Stocks

Simply Wall St.
·
26 Mar

Protalix BioTherapeutics to Present at the iAccess Alpha Virtual Best Ideas Spring Conference 2025

PR Newswire
·
24 Mar

Is Protalix BioTherapeutics (PLX) The High Growth Low Debt Stock to Invest in Now?

Insider Monkey
·
23 Mar

PLX: 2024 Results

Zacks Small Cap Research
·
18 Mar

Protalix BioTherapeutics Reports Record Revenue and Clinical Progress

TIPRANKS
·
18 Mar

Protalix BioTherapeutics Says With Debt Fully Repaid, It's Well-Positioned To Execute Strategy Through 2025 And Beyond

Benzinga
·
17 Mar

Protalix BioTherapeutics FY 2024 GAAP EPS $0.04 Beats $0.01 Estimate, Sales $53.40M Miss $53.94M Estimate

Benzinga
·
17 Mar

Press Release: Protalix BioTherapeutics Reports Fiscal Year 2024 Financial and Business Results

Dow Jones
·
17 Mar

Protalix BioTherapeutics to Announce Fiscal Year 2024 Financial and Business Results on March 17, 2025

PR Newswire
·
10 Mar

Balanced Outlook for PLUXEE N.V. Amid Spin-Out Opportunities and Market Challenges

TIPRANKS
·
10 Feb

3 US Penny Stocks With Market Caps Under $400M To Watch

Simply Wall St.
·
06 Feb

Protalix BioTherapeutics to Participate in the 2025 BIO CEO & Investor Conference

PR Newswire
·
04 Feb

Protalix price target raised to $15 from $10 at H.C. Wainwright

TIPRANKS
·
03 Feb

PLX: Revisiting the Thesis

Zacks Small Cap Research
·
03 Feb

Barclays Sticks to Their Hold Rating for PLUXEE N.V. (PLX)

TIPRANKS
·
30 Jan